Our Technology
ADENO-DERIVED VIRUS-LIKE PARTICLES
Our core technology harnesses the exceptional delivery capabilities and large packaging capacity of adenoviral vector based particles, lacking all viral genes. Our proprietary manufacturing approach allows the production of contaminant free proteinaceous particles carrying over 30Kb of exogenous DNA. This platform, IcoGenesis, enables scalable, high-efficiency VLP production, unlocking new possibilities in targeted drug delivery and immunotherapy.
We're helping to improve clinical outcomes.
Our focus is on resolving unmet clinical needs, deploying our technologies where they can offer the greatest patient benefit. Our research teams are developing treatments for some of the most challenging genetic disorders, including ocular diseases and cancer. We are currently advancing our pipeline of non-infectious, customizable VLPs for conditions with urgent unmet clinical needs.
THE TECHNOLOGY - APPLIED
The clinical use of adeno-based VLPs has long been hampered by contamination of preparations with the helper vector used to create them. Our manufacturing technology focuses on resolving this long standing issue. By tightly controlling the life cycle of one of the most complex vectors in biology, we are able to eliminate this contamination, making them safe and clinically viable.
